Corrigendum: Specialty bias in treatment recommendations and quality of life among radiation oncologists and urologists for localized prostate cancer (Prostate Cancer and Prostatic Diseases (2014) DOI: 10.1038/pcan.2014.3);Specialty bias in treatment recommendations and quality of life among radiation oncologists and urologists for localized prostate cancer

Prostate Cancer and Prostatic Diseases

Volumn 17, Issue 2, 2014, Pages 163-169

  Kim, S P ^a,b   Gross, C P ^a,b   Nguyen, P Y ^c   Smaldone, M C ^d   Thompson, R H ^e   Shah, N D ^e   Kutikov, A ^d   Han, L C ^e   Karnes, R J ^e   Ziegenfuss, J Y ^f   Tilburt, J C ^e  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d TEMPLE UNIVERSITY HEALTH SYSTEM   (United States)

^e MAYO CLINIC   (United States)

^f HEALTHPARTNERS INSTITUTE   (United States)

Author keywords

outcomes; quality of life; survey; treatment recommendations

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; ARTICLE; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL DECISION MAKING; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GLEASON SCORE; HIGH RISK PATIENT; HUMAN; LOW RISK PATIENT; MALE; PHYSICIAN ATTITUDE; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; RADIATION ONCOLOGIST; TREATMENT INDICATION; URINE INCONTINENCE; UROLOGIST; CANCER GRADING; CLINICAL PRACTICE; DECISION MAKING; HEALTH PERSONNEL ATTITUDE; METABOLISM; MIDDLE AGED; ONCOLOGY; PATHOLOGY; PHYSICIAN; PROCEDURES; PROSTATE; PROSTATIC NEOPLASMS; UROLOGY;

ADULT; ATTITUDE OF HEALTH PERSONNEL; DECISION MAKING; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; PHYSICIAN'S PRACTICE PATTERNS; PHYSICIANS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; QUALITY OF LIFE; RADIATION ONCOLOGY; UROLOGY;

EID: 84901195367     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2014.14     Document Type: Erratum

References (31)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29
2. Cooperberg MR, Broering JM, Carroll PR. Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol 2010; 28: 1117-1123
3. Cooperberg MR, Lubeck DP, Mehta SS, Carroll PR. Time trends in clinical risk stratification for prostate cancer: Implications for outcomes (data from CaPSURE). J Urol 2003; 170(6 Pt 2): S21-S25, discussion S26-27
4. Mohler J, Babaian RJ, Bahnson RR, Boston B, D'Amico A, Eastham JA et al. Prostate cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 2007; 5: 650-683
5. Thompson I, Thrasher JB, Aus G, Burnett AL, Canby-Hagino ED, Cookson MS et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol 2007; 177: 2106-2131
6. Wilt TJ, MacDonald R, Rutks I, Shamliyan TA, Taylor BC, Kane RL. Systematic review: Comparative effectiveness and harms of treatments for clinically localized prostate cancer. Ann Intern Med 2008; 148: 435-448
7. Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008; 358: 1250-1261
8. Miller DC, Sanda MG, Dunn RL, Montie JE, Pimentel H, Sandler HM et al. Long-Term outcomes among localized prostate cancer survivors: Health-related quality-of-life changes after radical prostatectomy, external radiation, and brachytherapy. J Clin Oncol 2005; 23: 2772-2780
9. Litwin MS, Hays RD, Fink A, Ganz PA, Leake B, Leach GE et al. Quality-of-life outcomes in men treated for localized prostate cancer. JAMA 1995; 273: 129-135
10. Resnick MJ, Koyama T, Fan KH, Albertsen PC, Goodman M, Hamilton AS et al. Long-Term functional outcomes after treatment for localized prostate cancer. N Engl J Med 2013; 368: 436-445
11. Bill-Axelson A, Holmberg L, Ruutu M, Garmo H, Stark JR, Busch C et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2011; 364: 1708-1717
12. Wilt TJ, Brawer MK, Jones KM, Barry MJ, Aronson WJ, Fox S et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 2012; 367: 203-213
13. American Medical Association. Getting the most for our health care dollars: Shared decision-making. 2010, http://www.ama-Assn.org/resources/doc/ healthcare- costs/shared-decision-making.pdf. Accessed 2013
14. Fowler FJ Jr., Gallagher PM, Bynum JP, Barry MJ, Lucas FL, Skinner JS. Decisionmaking process reported by Medicare patients who had coronary artery stenting or surgery for prostate cancer. J Gen Intern Med 2012; 27: 911-916
15. Zikmund-Fisher BJ, Couper MP, Singer E, Levin CA, Fowler Jr FJ, Ziniel S et al. The DECISIONS study: A nationwide survey of United States adults regarding 9 common medical decisions. Med Decis Making 2010; 30(5 Suppl): 20S-34S.
16. Jang TL, Bekelman JE, Liu Y, Bach PB, Basch EM, Elkin EB et al. Physician visits prior to treatment for clinically localized prostate cancer. Arch Intern Med 2010; 170: 440-450
17. Aizer AA, Paly JJ, Zietman AL, Nguyen PL, Beard CJ, Rao SK et al. Multidisciplinary care and pursuit of active surveillance in low-risk prostate cancer. J Clin Oncol 2012; 30: 3071-3076
18. Sommers BD, Beard CJ, D'Amico AV, Kaplan I, Richie JP, Zeckhauser RJ. Predictors of patient preferences and treatment choices for localized prostate cancer. Cancer 2008; 113: 2058-2067
19. Moore MJ, O'Sullivan B, Tannock IF. How expert physicians would wish to be treated if they had genitourinary cancer. J Clin Oncol 1988; 6: 1736-1745
20. Grimm P, Billiet I, Bostwick D, Dicker AP, Frank S, Immerzeel J et al. Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group. BJU Int 2012; 109(Suppl 1): 22-29
21. Stephenson AJ, Kattan MW, Eastham JA, Bianco Jr FJ, Yossepowitch O, Vickers AJ et al. Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol 2009; 27: 4300-4305
22. Stephenson AJ, Kattan MW, Eastham JA, Dotan ZA, Bianco Jr FJ, Lilja H et al. Defining biochemical recurrence of prostate cancer after radical prostatectomy: A proposal for a standardized definition. J Clin Oncol 2006; 24: 3973-3978
23. Critz FA, Benton JB, Shrake P, Merlin ML. 25-year disease-free survival rate after irradiation for prostate cancer calculated with the prostate specific antigen definition of recurrence used for radical prostatectomy. J Urol 2013; 189: 878-883
24. Zietman AL, Bae K, Slater JD, Shipley WU, Efstathiou JA, Coen JJ et al. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: Long-Term results from proton radiation oncology group/american college of radiology 95-09. J Clin Oncol 2010; 28: 1106-1111
25. Cooperberg MR, Lubeck DP, Meng MV, Mehta SS, Carroll PR. The changing face of low-risk prostate cancer: Trends in clinical presentation and primary management. J Clin Oncol 2004; 22: 2141-2149
26. Role of active surveillance in the management of men with localized prostate cancer 2011, http://consensus.nih.gov/2011/prostategetinvolved.htm. Accessed, 1 February 2013
27. Jacobs BL, Zhang Y, Schroeck FR, Skolarus TA, Wei JT, Montie JE et al. Use of advanced treatment technologies among men at low risk of dying from prostate cancer. JAMA 2013; 309: 2587-2595
28. Fowler FJ Jr., McNaughton Collins M, Albertsen PC, Zietman A, Elliott DB, Barry MJ. Comparison of recommendations by urologists and radiation oncologists for treatment of clinically localized prostate cancer. JAMA 2000; 283: 3217-3222
29. Kim SP, Shah ND, Karnes RJ, Weight CJ, Shippee ND, Han LC et al. Hospitalization costs for radical prostatectomy attributable to robotic surgery. Eur Urol 2012; 64: 11-16
30. Asch DA, Jedrziewski MK, Christakis NA. Response rates to mail surveys published in medical journals. J Clin Epidemiol 1997; 50: 1129-1136
31. Cummings SM, Savitz LA, Konrad TR. Reported response rates to mailed physician questionnaires. Health Serv Res 2001; 35: 1347-1355